GlobeNewswire: Tufts Center for the Study of Drug Development Contains the last 10 of 139 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T07:08:54ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/11/02/2325455/0/en/Diversity-of-Investigative-Site-Staff-Highly-Associated-with-the-Diversity-of-Patients-Enrolled-in-Clinical-Trials-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html?f=22&fvtc=4&fvtv=41644Diversity of Investigative Site Staff Highly Associated with the Diversity of Patients Enrolled in Clinical Trials, According to Tufts Center for the Study of Drug Development2021-11-02T13:00:00Z<![CDATA[BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- A new study just released by the Tufts Center for the Study of Drug Development (CSDD) shows that the proportion of a given race or ethnicity among investigative site personnel closely aligns with the corresponding race and ethnicity of patients enrolled in clinical trials at that site. The study also found that worldwide, regardless of geographic location, the diversity of patients enrolled in clinical trials is highly correlated with site personnel diversity.]]>https://www.globenewswire.com/news-release/2021/05/04/2222347/0/en/Protocol-Complexity-and-Patient-Enrollment-Intensify-Challenges-in-Oncology-Clinical-Trials-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html?f=22&fvtc=4&fvtv=41644Protocol Complexity and Patient Enrollment Intensify Challenges in Oncology Clinical Trials, According to Tufts Center for the Study of Drug Development2021-05-04T13:00:00Z<![CDATA[New Tufts Center for the Study of Drug Development Analysis Benchmarks Phase II, III Clinical Trials New Tufts Center for the Study of Drug Development Analysis Benchmarks Phase II, III Clinical Trials]]>https://www.globenewswire.com/news-release/2021/03/02/2185382/0/en/Planned-and-Unplanned-Mid-Study-Updates-Pose-Major-Challenge-to-Clinical-Trial-Timelines-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html?f=22&fvtc=4&fvtv=41644Planned and Unplanned Mid-Study Updates Pose Major Challenge to Clinical Trial Timelines, According to Tufts Center for the Study of Drug Development2021-03-02T14:00:00Z<![CDATA[Tufts Center for the Study of Drug Development Analysis Finds Larger Pharmaceutical Companies Experience Longer Delays due to Mid-Study Updates]]>https://www.globenewswire.com/news-release/2021/01/12/2157143/0/en/Rising-Protocol-Design-Complexity-Is-Driving-Rapid-Growth-in-Clinical-Trial-Data-Volume-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html?f=22&fvtc=4&fvtv=41644Rising Protocol Design Complexity Is Driving Rapid Growth in Clinical Trial Data Volume, According to Tufts Center for the Study of Drug Development2021-01-12T14:00:00Z<![CDATA[New Tufts Center for the Study of Drug Development Study Updates and Expands Earlier Benchmarks New Tufts Center for the Study of Drug Development Study Updates and Expands Earlier Benchmarks]]>https://www.globenewswire.com/news-release/2020/12/08/2141386/0/en/Kenneth-I-Kaitin-to-Retire-from-the-Tufts-Center-for-the-Study-of-Drug-Development-after-Leading-the-Organization-for-23-Years.html?f=22&fvtc=4&fvtv=41644Kenneth I Kaitin to Retire from the Tufts Center for the Study of Drug Development after Leading the Organization for 23 Years2020-12-08T14:00:00Z<![CDATA[Kenneth A. Getz to Be Next Director of the Tufts Center for the Study of Drug Development Kenneth A. Getz to Be Next Director of the Tufts Center for the Study of Drug Development]]>https://www.globenewswire.com/news-release/2020/11/12/2125655/0/en/Transition-to-Decentralized-Clinical-Trials-during-the-Coronavirus-Pandemic-Is-far-More-Nuanced-than-Expected-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html?f=22&fvtc=4&fvtv=41644Transition to Decentralized Clinical Trials during the Coronavirus Pandemic Is far More Nuanced than Expected, According to Tufts Center for the Study of Drug Development2020-11-12T14:00:00Z<![CDATA[Select virtual and remote approaches—including telemedicine and e-consent—have seen more rapid adoption, Tufts CSDD found Select virtual and remote approaches—including telemedicine and e-consent—have seen more rapid adoption, Tufts CSDD found]]>https://www.globenewswire.com/news-release/2020/09/15/2093783/0/en/New-Anti-infective-Drugs-Had-a-14-Speed-Advantage-vs-Other-Drugs-During-2000-19-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html?f=22&fvtc=4&fvtv=41644New Anti-infective Drugs Had a 14% Speed Advantage vs. Other Drugs During 2000-19, According to Tufts Center for the Study of Drug Development2020-09-15T13:00:00Z<![CDATA[Anti-infectives were more likely to receive expedited program designation, Tufts CSDD found Anti-infectives were more likely to receive expedited program designation, Tufts CSDD found]]>https://www.globenewswire.com/news-release/2020/08/06/2074277/0/en/MEDIA-ADVISORY-Expert-Commentary-and-Insight-Available-on-COVID-19-Drug-Development.html?f=22&fvtc=4&fvtv=41644MEDIA ADVISORY: Expert Commentary and Insight Available on COVID-19 Drug Development2020-08-06T13:00:00Z<![CDATA[Perspectives on COVID-19 Vaccine and Therapeutic Development from Tufts Center for the Study of Drug Development]]>https://www.globenewswire.com/news-release/2020/07/16/2063362/0/en/Faster-New-Drug-Approval-Times-Are-More-Than-Offset-by-Longer-Clinical-Times-in-U-S-According-to-Tufts-Center-for-the-Study-of-Drug-Development.html?f=22&fvtc=4&fvtv=41644Faster New Drug Approval Times Are More Than Offset by Longer Clinical Times in U.S., According to Tufts Center for the Study of Drug Development2020-07-16T13:00:00Z<![CDATA[For drugs in expedited development programs, average total clinical and approval time was 11% lower For drugs in expedited development programs, average total clinical and approval time was 11% lower]]>https://www.globenewswire.com/news-release/2020/05/12/2031952/0/en/Tufts-Center-for-the-Study-of-Drug-Development-Establishes-Demographic-Benchmarks-for-Pivotal-Clinical-Trials-Showing-Areas-of-Under-Representation.html?f=22&fvtc=4&fvtv=41644Tufts Center for the Study of Drug Development Establishes Demographic Benchmarks for Pivotal Clinical Trials, Showing Areas of Under-Representation2020-05-12T13:00:00Z<![CDATA[Disparity of impacts of the coronavirus pandemic underscore need for better demographic representation in trials Disparity of impacts of the coronavirus pandemic underscore need for better demographic representation in trials]]>